Online citations, reference lists, and bibliographies.
← Back to Search

Management Of Dyslipidemia In Patients With Hypertension, Diabetes, And Metabolic Syndrome

S. Srikanth, P. Deedwania
Published 2016 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy Visualize in Litmaps
Share
Reduce the time it takes to create your bibliography by a factor of 10 by using the world’s favourite reference manager
Time to take this seriously.
Get Citationsy
Purpose of ReviewThe purpose of this review is to discuss dyslipidemia in the various common clinical conditions including hypertension, diabetes mellitus, and metabolic syndrome and review the current therapeutic strategy in these settings.Recent FindingsDyslipidemias are common in patients with hypertension, diabetes mellitus, and metabolic syndrome. Epidemiologic studies have shown a strong correlation between serum lipid levels and risk of atherosclerotic cardiovascular disease. Multifactorial intervention strategies aimed at controlling lipids, blood pressure, and blood glucose simultaneously achieve maximal reductions in cardiovascular risk.SummaryDyslipidemia and metabolic abnormalities are strongly associated with atherosclerosis and worse cardiovascular outcomes. While pharmacotherapy with statins has been proven to be beneficial for dyslipidemia, lifestyle modification emphasizing weight loss and regular exercise is an essential component of the interventional strategy. The common thread underlying atherosclerosis and metabolic abnormalities is endothelial dysfunction. Improved understanding of the role of endothelium in health and disease can potentially lead to novel therapies that may preempt development of atherosclerosis and its complications.
This paper references
10.1161/01.CIR.95.1.1
Small LDL, atherogenic dyslipidemia, and the metabolic syndrome.
S. Grundy (1997)
10.1056/NEJM199708283370904
Fatal pulmonary hypertension associated with short-term use of fenfluramine and phentermine.
E. Mark (1997)
10.1056/NEJM199708283370901
Valvular heart disease associated with fenfluramine-phentermine.
H. Connolly (1997)
10.1136/bmj.316.7134.823
Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom prospective diabetes study (UKPDS: 23)
R. Turner (1998)
10.1016/S0002-9149(99)00132-0
Additional reduction in blood pressure after cholesterol-lowering treatment by statins (lovastatin or pravastatin) in hypercholesterolemic patients using angiotensin-converting enzyme inhibitors (enalapril or lisinopril).
A. Sposito (1999)
10.1056/NEJM200001203420301
Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients.
S. Yusuf (2000)
10.1161/HY1101.092845
Enalapril Attenuates Oxidative Stress in Diabetic Rats
E. D. de Cavanagh (2001)
10.1016/S0140-6736(02)08089-3
Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol
B. Dahlöf (2002)
10.1001/JAMA.288.23.2981
Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
C. Furberg (2002)
National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)
S. Grundy (2002)
10.1056/NEJMOA012512
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
W. Knowler (2002)
10.1038/sj.ijo.0802217
Metabolic benefits associated with sibutramine therapy
G. Krejs (2002)
10.1161/01.HYP.0000078490.59735.6E
Blockade of the Renin-Angiotensin System Increases Adiponectin Concentrations in Patients With Essential Hypertension
M. Furuhashi (2003)
10.1016/S0140-6736(03)13636-7
MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial
R. Collins (2003)
10.1096/fj.02-0063fje
Enalapril and losartan attenuate mitochondrial dysfunction in aged rats
E. D. de Cavanagh (2003)
10.1161/01.CIR.0000075572.40158.77
Exercise and physical activity in the prevention and treatment of atherosclerotic cardiovascular disease: a statement from the Council on Clinical Cardiology (Subcommittee on Exercise, Rehabilitation, and Prevention) and the Council on Nutrition, Physical Activity, and Metabolism (Subcommittee on Ph
P. Thompson (2003)
El tratamiento hipolipemiante intensivo frente al moderado con estatinas tras síndromes coronarios agudos
C. Cannon (2004)
10.1161/01.CIR.0000133317.49796.0E
Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines
S. Grundy (2004)
10.2337/DIACARE.27.1.155
XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients.
J. Torgerson (2004)
10.1056/NEJMOA040583
Intensive versus moderate lipid lowering with statins after acute coronary syndromes.
C. Cannon (2004)
10.1001/JAMA.292.12.1440
Effect of a mediterranean-style diet on endothelial dysfunction and markers of vascular inflammation in the metabolic syndrome: a randomized trial.
K. Esposito (2004)
10.1016/S0140-6736(04)16895-5
Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial
H. Colhoun (2004)
10.1185/030079904125004466
The ORlistat and CArdiovascular risk profile in patients with metabolic syndrome and type 2 DIAbetes (ORliCARDIA) study
T. P. Didangelos (2004)
10.1007/S11883-005-0037-X
Remnant lipoproteins and atherosclerosis
T. Twickler (2005)
10.1016/S0140-6736(05)67185-1
Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled tri
B. Dahlöf (2005)
10.1161/CIRCULATIONAHA.104.532499
Non-high-density lipoprotein cholesterol and apolipoprotein B in the prediction of coronary heart disease in men.
T. Pischon (2005)
10.1056/NEJMOA054013
Sequence variations in PCSK9, low LDL, and protection against coronary heart disease.
J. Cohen (2006)
10.1159/000095324
Role of the renin-angiotensin- aldosterone system in the metabolic syndrome.
S. Engeli (2006)
10.1161/CIRCULATIONAHA.106.648642
Consistently Stable or Decreased Body Mass Index in Young Adulthood and Longitudinal Changes in Metabolic Syndrome Components: The Coronary Artery Risk Development in Young Adults Study
D. Lloyd-Jones (2007)
10.2337/dc07-1231
Mediterranean Diet Inversely Associated With the Incidence of Metabolic Syndrome
Arancha Tortosa (2007)
10.1111/j.1365-2710.2007.00817.x
The endocannabinoid system and rimonabant: a new drug with a novel mechanism of action involving cannabinoid CB1 receptor antagonism – or inverse agonism – as potential obesity treatment and other therapeutic use
S. Xie (2007)
10.2146/060258
Rimonabant: a novel selective cannabinoid-1 receptor antagonist for treatment of obesity.
P. Patel (2007)
10.1161/CIRCULATIONAHA.107.713438
Lipids, Apolipoproteins, and Their Ratios in Relation to Cardiovascular Events With Statin Treatment
J. Kastelein (2008)
Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Detection, Evaluation, and Treatment of High Blood Cholesterol Education Program (NCEP) Expert Panel on Executive Summary of the Third Report of the National
W. Taylor (2009)
10.1016/S0140-6736(10)60888-4
Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
F. Greenway (2010)
10.1056/NEJMoa1003114
Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects.
W. James (2010)
10.1016/S0140-6736(10)61350-5
Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials
A. Maggioni (2010)
10.1016/S0140-6736(10)61350-5
Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials.
C. Baigent (2010)
10.1056/NEJMoa1001122
Effect of nateglinide on the incidence of diabetes and cardiovascular events.
R. Holman (2010)
10.1038/oby.2010.147
Weight Loss With Naltrexone SR/Bupropion SR Combination Therapy as an Adjunct to Behavior Modification: The COR‐BMOD Trial
T. Wadden (2011)
10.1056/NEJMoa1107579
Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy.
W. Boden (2011)
10.1136/bmj.d7771
Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials
T. Vilsbøll (2012)
10.1016/S0140-6736(12)62027-3
Statins for people at low risk of cardiovascular disease – Authors' reply
B. Mihaylova (2012)
10.1016/j.atherosclerosis.2011.10.032
The expression of IGFs and IGF binding proteins in human carotid atherosclerosis, and the possible role of IGF binding protein-1 in the regulation of smooth muscle cell proliferation.
J. Wang (2012)
10.1016/S0140-6736(12)60367-5
The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials.
B. Mihaylova (2012)
10.1038/ijo.2011.158
Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide
A. Astrup (2012)
10.1016/j.jacl.2013.10.001
An International Atherosclerosis Society Position Paper: global recommendations for the management of dyslipidemia.
S. Grundy (2013)
10.1016/j.ahj.2013.07.012
Design of the liraglutide effect and action in diabetes: evaluation of cardiovascular outcome results (LEADER) trial.
S. Marso (2013)
10.1186/1741-7015-11-117
Immunity, atherosclerosis and cardiovascular disease
J. Frostegård (2013)
10.2337/dc13-0234
Effects of Naltrexone Sustained- Release/Bupropion Sustained-Release Combination Therapy on Body Weight and Glycemic Parameters in Overweight and Obese Patients With Type 2 Diabetes
P. Hollander (2013)
10.1093/eurheartj/ehs411
Update on acute coronary syndromes: the pathologists' view.
E. Falk (2013)
10.1016/j.jacc.2012.08.1026
Remnant cholesterol as a causal risk factor for ischemic heart disease.
A. Varbo (2013)
10.1002/oby.20309
A Randomized, Phase 3 Trial of Naltrexone SR/Bupropion SR on Weight and Obesity-related Risk Factors (COR-II)
C. Apovian (2013)
10.1161/01.cir.0000437738.63853.7a
2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.
N. Stone (2014)
10.2147/DMSO.S38979
Management of obesity and cardiometabolic risk – role of phentermine/extended release topiramate
A. Sweeting (2014)
10.1016/j.jacc.2014.01.088
Nonpharmacological lipoprotein apheresis reduces arterial inflammation in familial hypercholesterolemia.
Diederik F. van Wijk (2014)
10.1056/NEJMoa1300955
Effects of extended-release niacin with laropiprant in high-risk patients.
M. Landray (2014)
10.1056/NEJMoa1405386
Inactivating mutations in NPC1L1 and protection from coronary heart disease.
N. Stitziel (2014)
10.1136/bmj.g4379
Effect on cardiovascular risk of high density lipoprotein targeted drug treatments niacin, fibrates, and CETP inhibitors: meta-analysis of randomised controlled trials including 117 411 patients
D. Keene (2014)
10.1097/HCR.0000000000000112
Treatment of Obesity in 2015
A. Shukla (2015)
10.1056/NEJMoa1501031
Efficacy and safety of alirocumab in reducing lipids and cardiovascular events.
J. Robinson (2015)



This paper is referenced by
10.1016/J.IHJ.2021.04.008
The emerging role of gut microbiota in cardiovascular diseases.
Dilip Kumar (2021)
10.21203/RS.3.RS-568280/V1
The Interaction Effects of BMI and Dyslipidemia for Hypertension in Adults: A Cross-Sectional Survey
N. Tang (2021)
10.22038/ijbms.2020.41638.9832
An overview of glucagon-like peptide-1 receptor agonists for the treatment of metabolic syndrome: A drug repositioning
Maryam Rameshrad (2020)
10.1017/S136898002000289X
BMI, high-sensitivity C-reactive protein and the conversion from metabolically healthy to unhealthy phenotype in Chinese adults: a cohort study.
R. Xu (2020)
10.21315/mjms2020.27.6.5
Hypolipidaemic and Insulin Secretagogue Activities of (R)-(−)-Carvone
M. A. Abbas (2020)
10.25122/jml-2020-0073
Prevalence and Intensity of Periodontal Disease in Individuals with Metabolic Syndrome
T. А. Hlushchenko (2020)
10.1016/j.dsx.2020.03.018
Effect of green tea extract on lipid profile in patients with type 2 diabetes mellitus: A systematic review and meta-analysis.
Omid Asbaghi (2020)
10.1186/s12933-020-01037-0
Time-varying and dose-dependent effect of long-term statin use on risk of type 2 diabetes: a retrospective cohort study
Eonji Na (2020)
10.30574/WJBPHS.2020.4.1.0077
The magnitude of high blood pressure and its risk factors in the western region of Algeria
Hamza Nadjib Merad-boudia (2020)
EFFICACY AND SAFETY OF TURMERIC IN LOWERING BLOOD LIPID LEVELS AND GLUCOSE IN RATS FED HIGH-FAT DIETS
Elsayed El-Sahar (2020)
10.29309/tpmj/2020.27.05.4040
Prevalence of dyslipidemia in young adults.
Mir Tahir Hussain Talpur (2020)
10.35666/ghtbh.2019.52.02
Curcumin : Phytochemical Therapy in the Treatment of Hyperlipidemia
Pehlivanović B.a (2019)
10.1159/000501631
Regulation of iRhom-2/Tumor Necrosis Factor-α Converting Enzyme Pathway and Oxidative Stress Protects the Renal Injury with Anemonin in Streptozotocin-Induced Diabetic Nephropathy Neonatal Rat Model
L. Qiao (2019)
10.1186/s12944-019-0987-6
Separate and combined associations of physical activity and obesity with lipid-related indices in non-diabetic and diabetic patients
Y. Zhang (2019)
10.1142/S2575900019500071
Dyslipidemia associated with body constitution in Traditional Chinese Medicine
Qiuping Li (2019)
10.1007/s40199-019-00238-7
Pharmacology of dipeptidyl peptidase-4 inhibitors and its use in the management of metabolic syndrome: a comprehensive review on drug repositioning
Maryam Rameshrad (2019)
10.47196/DIAB.V51I2.68
INTERACCIONES FARMACOLÓGICAS DE ESTATINAS CON AGENTES ANTIDIABÉTICOS NO INSULÍNICOS
Cristian Suárez Cordo (2018)
Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy Dovepress
Haohai Huang (2018)
10.1016/B978-0-12-805253-2.00001-8
Overview of Autophagy and Cardiometabolic Syndrome
A. Aroor (2018)
10.23751/PN.V20I1.6228
The effects of catechins on related risk factors with Type 2 diabetes: a review
M. Alipour (2018)
10.1016/j.jacc.2018.02.057
Dangers and Long-Term Outcomes in Metabolically Healthy Obesity: The Impact of the Missing Fitness Component.
P. Deedwania (2018)
10.2147/DMSO.S185672
Quantifying the effects of spirulina supplementation on plasma lipid and glucose concentrations, body weight, and blood pressure
Haohai Huang (2018)
The Influencing Factors of Serum Lipids among Middle-aged Women in Northeast China
X. Zhang (2018)
10.1177/1559325818794530
Assessment Through the Short Physical Performance Battery of the Functionality in Individuals With Metabolic Syndrome Exposed to Whole-Body Vibration Exercises
L. Paineiras-Domingos (2018)
10.1186/s12937-017-0293-y
Efficacy and safety of turmeric and curcumin in lowering blood lipid levels in patients with cardiovascular risk factors: a meta-analysis of randomized controlled trials
S. Qin (2017)
10.1016/j.cbi.2017.02.012
Hypotensive effects of genistein: From chemistry to medicine.
A. Sureda (2017)
10.1155/2017/1896746
Correlation between Traditional Chinese Medicine Constitution and Dyslipidemia: A Systematic Review and Meta-Analysis
Ye-Lin Ma (2017)
10.7759/cureus.1347
Correlation between Glycated Hemoglobin and Triglyceride Level in Type 2 Diabetes Mellitus
Syeda Naqvi (2017)
10.4172/2165-7904.1000361
Regression of Non-Alcoholic Fatty Liver by Metabolic Reduction: Phototherapy in Association with Aerobic Plus Resistance Training In Obese Man - A Pilot Study
Antonio Eduardo de Aquino Junior (2017)
10.12659/MSM.906027
Effect of Cinnamaldehyde on Glucose Metabolism and Vessel Function
X. Guo (2017)
10.1111/liv.13302
Therapies in non‐alcoholic steatohepatitis (NASH)
Abdul M. Oseini (2017)
Semantic Scholar Logo Some data provided by SemanticScholar